SCHEMBL24617618

SCHEMBL24617618

CNC(=O)c1cc(F)cc(C(C)n2ccc3cc(-c4cn[nH]c4C(F)(F)F)ccc3c2=O)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
WNT1 P04628 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
METAP2 P50579 6/20 0.34
ROCK2 O75116 2/20 0.34
ROCK1 Q13464 2/20 0.34
IDH1 O75874 1/20 0.34
XDH P47989 1/20 0.34
LIPC P11150 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
TNIK Q9UKE5 1/20 0.33
CYP1A2 P05177 1/20 0.32
CDK2 P24941 1/20 0.32
CCNA1 P78396 1/20 0.32
MET P08581 2/20 0.31
EGFR P00533 1/20 0.31
USP30 Q70CQ3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24617623 0.90 WNT1 (0.37) WNT1GSK3BDYRK1AMETAP2ROCK2
SCHEMBL24616947 0.90 METAP2 (0.33) GSK3BMETAP2ROCK2ROCK1MET
SCHEMBL24616942 0.89 METAP2 (0.34) METAP2ROCK2ROCK1CYP1A2MET
SCHEMBL29778575 0.89 METAP2 (0.34) METAP2ROCK2ROCK1CYP1A2MET
SCHEMBL24617321 0.87 METAP2 (0.36) WNT1GSK3BDYRK1AMETAP2ROCK2
SCHEMBL24617373 0.87 METAP2 (0.36) WNT1GSK3BDYRK1AMETAP2ROCK2
SCHEMBL24617619 0.82 ROCK2 (0.41) WNT1GSK3BDYRK1AMETAP2ROCK2
SCHEMBL29778479 0.82 LIPC (0.34) WNT1GSK3BDYRK1AMETAP2ROCK2
SCHEMBL24616946 0.81 ROCK2 (0.37) METAP2ROCK2ROCK1TNIKEGFR
SCHEMBL29778454 0.81 ROCK2 (0.37) METAP2ROCK2ROCK1TNIKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 CN disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 WNT1 2787/4885GSK3B 63/4885DYRK1A 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.